An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer (CRPC).

Carmel Pezaro; Mark Rosenthal; Howard Gurney; Ian Davis; Craig R Underhill; Michael J Boyer; Dusan Kotasek; Benjamin Solomon; Guy Toner

doi:10.1097/COC.0b013e31818b946b

An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer (CRPC).

Carmel Pezaro, Mark Rosenthal, Howard Gurney, Ian Davis, Craig R Underhill, Michael J Boyer, Dusan Kotasek, Benjamin Solomon, Guy Toner

Eastern Health Clinical School

Research output: Contribution to journal › Article › Research › peer-review

43 Citations (Scopus)

Original language	English
Pages (from-to)	338 - 341
Number of pages	4
Journal	American Journal of Clinical Oncology
Volume	32
Issue number	4
DOIs	https://doi.org/10.1097/COC.0b013e31818b946b
Publication status	Published - 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/COC.0b013e31818b946b

Cite this

Pezaro, Carmel ; Rosenthal, Mark ; Gurney, Howard ; Davis, Ian ; Underhill, Craig R ; Boyer, Michael J ; Kotasek, Dusan ; Solomon, Benjamin ; Toner, Guy. / An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer (CRPC). In: American Journal of Clinical Oncology. 2009 ; Vol. 32, No. 4. pp. 338 - 341.

@article{61843df73629431392bedf7354a6838a,

title = "An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer (CRPC).",

author = "Carmel Pezaro and Mark Rosenthal and Howard Gurney and Ian Davis and Underhill, {Craig R} and Boyer, {Michael J} and Dusan Kotasek and Benjamin Solomon and Guy Toner",

year = "2009",

doi = "10.1097/COC.0b013e31818b946b",

language = "English",

volume = "32",

pages = "338 -- 341",

journal = "American Journal of Clinical Oncology",

issn = "0277-3732",

publisher = "Lippincott Williams & Wilkins",

number = "4",

}

An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer (CRPC). / Pezaro, Carmel; Rosenthal, Mark; Gurney, Howard; Davis, Ian; Underhill, Craig R; Boyer, Michael J; Kotasek, Dusan; Solomon, Benjamin; Toner, Guy.

In: American Journal of Clinical Oncology, Vol. 32, No. 4, 2009, p. 338 - 341.

Research output: Contribution to journal › Article › Research › peer-review

TY - JOUR

T1 - An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer (CRPC).

AU - Pezaro, Carmel

AU - Rosenthal, Mark

AU - Gurney, Howard

AU - Davis, Ian

AU - Underhill, Craig R

AU - Boyer, Michael J

AU - Kotasek, Dusan

AU - Solomon, Benjamin

AU - Toner, Guy

PY - 2009

Y1 - 2009

UR - http://www.ncbi.nlm.nih.gov/pubmed/19363437

U2 - 10.1097/COC.0b013e31818b946b

DO - 10.1097/COC.0b013e31818b946b

M3 - Article

VL - 32

SP - 338

EP - 341

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 4

ER -

An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer (CRPC).

UN SDGs

Access to Document

Other files and links

Cite this